Revenue and net profit grew significantly year-over-year but declined sequentially from the previous quarter. Regulatory inspections had no material impact, and the company maintained its focus on specialty chemicals for pharmaceuticals.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.